Hala Audi is Chief Alliance Officer at Univercells and the CEO of Univercells’ advisory
services business Unizima, a company dedicated to building biopharma infrastructure in
emerging markets to meet rising demand for vaccines and biologics.
Hala joined Univercells in January 2022 from a career in government and global public
health. She has 20 years of international experience leading projects that focused on
innovation in pharma economics, antimicrobial resistance and pandemic preparedness.
As an arbitration lawyer and during her governmental career, Hala also gained a deep
understanding of large public-private infrastructure and construction projects. She is a
law graduate from Université Paris-II Assas and Columbia University and obtained her
Masters in Public Administration by studying at Harvard Kennedy School and the LSE in
London.
About Univercells. Univercells transforms how biotech drugs are made so everyone,
everywhere can get them. Through cutting-edge bioprocessing and technology,
Univercells creates transformative platforms across drug discovery, development and
delivery. Its focus is to drive accessiblity, affordability and sustainability to eliminate
barriers for drug developers.
Collaborating with biotech and pharmaceutical companies, Univercells paves the way
for new vaccines and therapies targeting cancer, infectious diseases, and animal health.
With world-leading and mission-aligned stakeholders like the European Investment
Bank, the Global Health Investment Corporation and the Gates Foundation, Univercells is
poised to make a difference on a global scale.
About Unizima. Unizima is a biomanufacturing services and technology provider,bringing world class experience in biologics manufacturing to a range of clients in Africa
and the Middle East, including development, bulk production and fill and finish.
Flagship projects include the Institut Pasteur de Dakar’s Madiba vaccine facility;
supporting the tech transfer to Senegal of a new Measle Rubella vaccine manufactured
on Univercells Technologies equipment, funded by the Bill and Melinda Gates
Foundation; acting as technical expert for a new vaccine manufacutring plant in Nigeria,
and adivsing clients building new biologics facilities in the Arabian Gulf and North Africa.